-DOCSTART- -X- O
Nasal -X- _ O
administration -X- _ O
has -X- _ O
emerged -X- _ O
as -X- _ O
a -X- _ O
promising -X- _ O
and -X- _ O
attractive -X- _ O
route -X- _ O
for -X- _ O
vaccination -X- _ O
, -X- _ O
especially -X- _ O
for -X- _ O
the -X- _ O
prophylaxis -X- _ O
of -X- _ O
respiratory -X- _ O
diseases. -X- _ O
Our -X- _ O
previous -X- _ O
studies -X- _ O
have -X- _ O
shown -X- _ O
that -X- _ O
severe -X- _ B-Intervention
acute -X- _ I-Intervention
respiratory -X- _ I-Intervention
syndrome -X- _ I-Intervention
coronavirus -X- _ I-Intervention
( -X- _ I-Intervention
SARS-CoV -X- _ I-Intervention
) -X- _ I-Intervention
virus-like -X- _ I-Intervention
particles -X- _ I-Intervention
( -X- _ I-Intervention
VLPs -X- _ I-Intervention
) -X- _ I-Intervention
can -X- _ O
be -X- _ O
assembled -X- _ O
using -X- _ O
a -X- _ O
recombinant -X- _ O
baculovirus -X- _ O
( -X- _ O
rBV -X- _ O
) -X- _ O
expression -X- _ O
system -X- _ O
and -X- _ O
such -X- _ O
VLPs -X- _ B-Intervention
induce -X- _ O
specific -X- _ O
humoral -X- _ O
and -X- _ O
cellular -X- _ O
immune -X- _ O
responses -X- _ O
in -X- _ O
mice -X- _ B-Patient
after -X- _ O
subcutaneous -X- _ O
injection. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
mucosal -X- _ B-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
to -X- _ O
SARS-CoV -X- _ B-Intervention
VLPs -X- _ I-Intervention
in -X- _ O
a -X- _ O
mouse -X- _ B-Patient
model. -X- _ I-Patient
Mice -X- _ B-Patient
were -X- _ O
immunized -X- _ O
in -X- _ O
parallel -X- _ O
, -X- _ O
intraperitoneally -X- _ B-Intervention
or -X- _ I-Intervention
intranasally -X- _ I-Intervention
, -X- _ I-Intervention
with -X- _ I-Intervention
VLPs -X- _ I-Intervention
alone -X- _ I-Intervention
or -X- _ I-Intervention
with -X- _ I-Intervention
VLPs -X- _ I-Intervention
plus -X- _ I-Intervention
cytosine–phosphate–guanosine -X- _ I-Intervention
( -X- _ I-Intervention
CpG -X- _ I-Intervention
) -X- _ I-Intervention
. -X- _ O
Immune -X- _ O
responses -X- _ O
, -X- _ O
including -X- _ O
the -X- _ O
production -X- _ O
of -X- _ O
SARS-CoV-specific -X- _ O
serum -X- _ O
immunoglobulin -X- _ O
G -X- _ O
( -X- _ O
IgG -X- _ O
) -X- _ O
and -X- _ O
secretory -X- _ O
immunoglobulin -X- _ O
A -X- _ O
( -X- _ O
sIgA -X- _ O
) -X- _ O
, -X- _ O
were -X- _ O
determined -X- _ O
in -X- _ O
mucosal -X- _ O
secretions -X- _ O
and -X- _ O
tissues. -X- _ O
Both -X- _ B-Outcome
immunizations -X- _ I-Outcome
induced -X- _ I-Outcome
SARS-CoV-specific -X- _ I-Outcome
IgG -X- _ I-Outcome
, -X- _ I-Outcome
although -X- _ I-Outcome
the -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
IgG -X- _ I-Outcome
in -X- _ I-Outcome
groups -X- _ I-Outcome
immunized -X- _ I-Outcome
via -X- _ I-Outcome
the -X- _ I-Outcome
intraperitoneal -X- _ I-Outcome
( -X- _ I-Outcome
i.p. -X- _ I-Outcome
) -X- _ I-Outcome
route -X- _ I-Outcome
were -X- _ I-Outcome
higher. -X- _ I-Outcome
sIgA -X- _ I-Outcome
was -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
saliva -X- _ I-Outcome
in -X- _ I-Outcome
groups -X- _ I-Outcome
immunized -X- _ I-Outcome
intranasally -X- _ I-Outcome
but -X- _ I-Outcome
not -X- _ I-Outcome
in -X- _ I-Outcome
groups -X- _ I-Outcome
immunized -X- _ I-Outcome
intraperitoneally. -X- _ I-Outcome
CpG -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
adjuvant -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
IgA -X- _ I-Outcome
production -X- _ I-Outcome
in -X- _ I-Outcome
genital -X- _ I-Outcome
tract -X- _ I-Outcome
washes -X- _ I-Outcome
when -X- _ I-Outcome
administered -X- _ I-Outcome
intranasally -X- _ I-Outcome
but -X- _ I-Outcome
only -X- _ I-Outcome
affected -X- _ I-Outcome
IgA -X- _ I-Outcome
production -X- _ I-Outcome
in -X- _ I-Outcome
faeces -X- _ I-Outcome
samples -X- _ I-Outcome
when -X- _ I-Outcome
administered -X- _ I-Outcome
intraperitoneally. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
IgA -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
mucosal -X- _ I-Outcome
tissues -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
lung -X- _ I-Outcome
and -X- _ I-Outcome
intestine -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
CpG -X- _ I-Outcome
induced -X- _ I-Outcome
an -X- _ I-Outcome
increased -X- _ I-Outcome
level -X- _ I-Outcome
of -X- _ I-Outcome
IgA -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
intestine. -X- _ I-Outcome
Most -X- _ I-Outcome
importantly -X- _ I-Outcome
, -X- _ I-Outcome
neutralization -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
detected -X- _ I-Outcome
in -X- _ I-Outcome
sera -X- _ I-Outcome
after -X- _ I-Outcome
i.p. -X- _ I-Outcome
and -X- _ I-Outcome
intranasal -X- _ I-Outcome
( -X- _ I-Outcome
i.n. -X- _ I-Outcome
) -X- _ I-Outcome
immunizations. -X- _ I-Outcome
Secretions -X- _ I-Outcome
in -X- _ I-Outcome
genital -X- _ I-Outcome
tract -X- _ I-Outcome
washes -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
i.n. -X- _ I-Outcome
group -X- _ I-Outcome
also -X- _ I-Outcome
showed -X- _ I-Outcome
neutralization -X- _ I-Outcome
activity. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
VLPs -X- _ I-Outcome
that -X- _ I-Outcome
were -X- _ I-Outcome
administered -X- _ I-Outcome
intraperitoneally -X- _ I-Outcome
elicited -X- _ I-Outcome
cellular -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
as -X- _ I-Outcome
demonstrated -X- _ I-Outcome
by -X- _ I-Outcome
enzyme-linked -X- _ I-Outcome
immunospot -X- _ I-Outcome
( -X- _ I-Outcome
ELISPOT -X- _ I-Outcome
) -X- _ I-Outcome
assay -X- _ I-Outcome
analyses. -X- _ I-Outcome
In -X- _ O
summary -X- _ O
, -X- _ O
our -X- _ O
study -X- _ O
indicates -X- _ O
that -X- _ O
mucosal -X- _ B-Intervention
immunization -X- _ I-Intervention
with -X- _ I-Intervention
rBV -X- _ I-Intervention
SARS-CoV -X- _ I-Intervention
VLPs -X- _ I-Intervention
represent -X- _ O
an -X- _ O
effective -X- _ O
means -X- _ O
for -X- _ O
eliciting -X- _ B-Outcome
protective -X- _ I-Outcome
systemic -X- _ I-Outcome
and -X- _ I-Outcome
mucosal -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
against -X- _ O
SARS- -X- _ O
CoV -X- _ O
, -X- _ O
providing -X- _ O
important -X- _ O
information -X- _ O
for -X- _ O
vaccine -X- _ O
design -X- _ O
. -X- _ O

